At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BK4556 Gene Editing
Market Closed 12-19 16:00:00 EST
444.54
+8.54
+1.96%
High452.67Low437.00Vol21.35M
Open437.00D1 Closing436.00Amplitude3.59%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O338.84MT/O Rate--Tradable Shares0.00
P/B2.523691ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Beam Therapeutics (BEAM): Reassessing Valuation After New BEACON risto-cel Data in Sickle Cell Disease
Simply Wall St.  ·  12-19 13:20
Beam Therapeutics (BEAM): Reassessing Valuation After New BEACON risto-cel Data in Sickle Cell Disease
Sangamo Therapeutics Begins FDA Rolling Submission for ST-920 Gene Therapy in Fabry Disease
Reuters  ·  12-18 21:05
Sangamo Therapeutics Begins FDA Rolling Submission for ST-920 Gene Therapy in Fabry Disease
Sangamo Therapeutics Inc - Expects to Complete Bla Submission by Q2 2026
THOMSON REUTERS  ·  12-18 21:05
Sangamo Therapeutics Inc - Expects to Complete Bla Submission by Q2 2026
Coinbase to List 3 New Cryptocurrencies: Details
utoday  ·  12-16
Coinbase to List 3 New Cryptocurrencies: Details
Intellia Therapeutics CEO John M. Leonard Reports Disposal of Common Shares
Reuters  ·  12-13
Intellia Therapeutics CEO John M. Leonard Reports Disposal of Common Shares
Beam Therapeutics Nets $255 Million From Orbital Therapeutics Sale
Reuters  ·  12-12
Beam Therapeutics Nets $255 Million From Orbital Therapeutics Sale
Why Intellia Therapeutics (NTLA) Is Up 6.9% After Disclosing Serious Liver Safety Events In Lead CRISPR Trials
Simply Wall St.  ·  12-08
Why Intellia Therapeutics (NTLA) Is Up 6.9% After Disclosing Serious Liver Safety Events In Lead CRISPR Trials
Beam Therapeutics Reports Durable Efficacy and Safety for Risto-cel in Sickle Cell Disease Trial
Reuters  ·  12-06
Beam Therapeutics Reports Durable Efficacy and Safety for Risto-cel in Sickle Cell Disease Trial
Beam Therapeutics Reports Updated Data From Beacon Phase 1/2 Trial of Ristoglogene Autogetemcel (Risto-Cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (Scd) at American Society of Hematology (Ash) Annual Meeting
THOMSON REUTERS  ·  12-06
Beam Therapeutics Reports Updated Data From Beacon Phase 1/2 Trial of Ristoglogene Autogetemcel (Risto-Cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (Scd) at American Society of Hematology (Ash) Annual Meeting
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  12-06
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Beam Therapeutics (BEAM) Is Up 6.8% After Analyst Optimism Around Sickle Cell Base-Editing Progress - What's Changed
Simply Wall St.  ·  12-05
Beam Therapeutics (BEAM) Is Up 6.8% After Analyst Optimism Around Sickle Cell Base-Editing Progress - What's Changed

Introduction

Company Name.
BK4556
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--